The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| E-Paper
Search
+

Pharma firms discover glamour in dowdy APIs

Pharma firms discover glamour in dowdy APIs
Pharma firms discover glamour in dowdy APIs
The moot question is how sustainable is this current industry growth of the segment.

Synopsis

Pharma companies have posted smart growth in API sales for the quarter due to increased demand of certain APIs used in the Covid-19 treatment and the world-wide scramble for alternatives to China.

ET Intelligence Group: The Active pharmaceutical ingredients (API) business, once the less glamorous and least talked about part of pharma manufacturing, has now begun getting its due. Pharma companies - Sun Pharma, Dr Reddys Labs (DRL), Laurus Labs, Biocon and Alembic Pharma - have posted smart growth in API sales for the quarter due to increased demand of certain APIs used in the Covid-19 treatment and the world-wide scramble for alternatives
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

To Read the Full Story, Become an ET Prime Member

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Access the exclusive Economic Times stories, Editorial and Expert opinion

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times